Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controls
Journal of Crohn's and Colitis
; 16:i614-i615, 2022.
Article
in English
| EMBASE | ID: covidwho-1722367
ABSTRACT
Background:
The information on seroprevalence rates of COVID-19 infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in immunocompromised and immunocompetent IBD patients and healthy controls.Methods:
Patients with IBD under follow-up at the IBD clinic, All India Institute of Medical Sciences, New Delhi, were included. After obtaining informed consent, patients underwent SARS-CoV-2 antibody testing (chemiluminescent immunoassay Seimens kit IgG against antigen S1RBD) and information on demography, drug history, past history of COVID infection and vaccination status were noted. Patients with IBD on 5-aminosalicylic acid or not on any treatment were considered immunocompetent and those who had received steroids, thiopurines or methotrexate within 6 months of sample collection were considered immunocompromised.Results:
235 patients (51.9%-males;mean age at enrolment- 38.7±12.4 years;median disease duration-60 months [IQR36- 120]) (UC-69.4%, CD-28.9%, IBDU-1.7%) and 73 healthy controls (HCs- mean age-39.6± 10.9 years, 79% males) were enrolled from July 2020 - April 2021 (Table1). 128 (54.5%) patients were immunocompromised and 107 were immunocompetent (treatment details 5 ASA-72.3%, steroids-15.3%, Thiopurines-40%, methotrexate-2.6%). Seventy-four (31.5%) patients were positive for IgG antibody against SARS CoV2, 2 patients (0.9%) had previous history of COVID infection and none received COVID vaccine. Seroprevalence rates between immunocompromised and immunocompetent patients with IBD and healthy controls was similar (28.1% vs 36% vs 28%, p>0.05) (Figure1). Demographic and disease characteristics such as age, gender, disease type, disease activity in last 6 months, disease duration and medication use was similar between patients with positive and negative serology (Table2). There was progressive increase in seroprevalence from July 2020 to April 2021Conclusion:
Upto 1/3rd patients with IBD were seropositive for IgG SARS Cov2 antibody indicating asymptomatic COVID-19 infection. The seroprevalence was similar to healthy controls and was not different between immunocompromised and immunocompetent patients with IBD.
CD28 antigen; endogenous compound; immunoglobulin G; immunoglobulin G antibody; mesalazine; methotrexate; SARS-CoV-2 antibody; SARS-CoV-2 vaccine; steroid; unclassified drug; adult; asymptomatic coronavirus disease 2019; chemiluminescence immunoassay; conference abstract; controlled study; coronavirus disease 2019; demography; drug therapy; female; follow up; gender; human; India; inflammatory bowel disease; informed consent; major clinical study; male; nonhuman; serology; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Journal of Crohn's and Colitis
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS